公开(公告)号：EP2623118A4

公开(公告)日：2014-05-07

申请号：EP11828423

申请日：2011-09-27

申请人： KYORITSU SEIYAKU CORP

发明人： ASAI KEN-ICHI ,  KAWAKAMI KAZUO ,  MOCHIZUKI MASAMI

IPC分类号： C07K14/235 ,  A61K39/39 ,  A61P31/12 ,  A61P31/16

CPC分类号： A61K39/39 ,  A61K38/162 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/52 ,  A61K2039/5252 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/55594 ,  C07K14/235 ,  C12N2710/10034 ,  C12N2760/18034

摘要： [Problem to be Solved] The present invention provides a novel mucosal adjuvant. [Solution] The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal and the like at a surface of mucous membrane can enhance immunity at the surface of mucous membrane. Therefore, for example, preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of, for example, canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.